


HitGen Email Formats
Biotechnology Research • Building 6, No. 8 Huigu 1st East Road, China • 51-100 Employees
HitGen Email Formats
HitGen uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 48.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 48.2% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 24.1% |
{first name}@company.com | john@company.com | 12.4% |
{last name}.{first name}@company.com | doe.john@company.com | 8.9% |
{first name}{last name}@company.com | johndoe@company.com | 6.4% |
Key Contacts at HitGen
Greg Bial
Director Of Business Development
Jing Huang
Assistant Director Of Strategic Planning
Xuemin Cheng
Senior Director Of Computational Science
Jing Chen
Executive Director, Biology
Fangchao Liu
Associate Director Of Del Screening And Assay
Jinsen Chen
Executive Director Of Nucleic Acid Chemistry
Xiaoyu Tian
Director Of Strategic Alliances
Xiaoguang Bai
Director Of Medicinal Chemistry
Huiyong Ma
Director
Sen Gao
Director Of Del Platform,Hitgen Inc.
Company overview
| Headquarters | Building 6, No. 8 Huigu 1st East Road, Tianfu International Bio-Town Shuangliu District, Chengdu, Sichuan 610200, CN |
| Phone number | +862885197385 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Lead Generation, Drug Discovery, Hit Identification, Protein Production And Purification, Chemical Library Synthesis, Dna Encoded Libraries, Early Phase R&D, Hit Expansion Libraries, Screening Libraries, Structure-Based Drug Design, Fragment-Based Drug Discovery, E3 Ligases, New Molecular Entities, Synthetic Therapeutic Oligonucleotide, Targeted Protein Degradation, Oligonucleotides Based Therapeutics |
| Founded | 2012 |
| Employees | 51-100 |
| Socials |
About HitGen
HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), oligonucleotides based therapeutics technology (OBT), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
HitGen has 33 employees across 13 departments.
Departments
Number of employees
HitGen Tech Stack
Discover the technologies and tools that power HitGen's digital infrastructure, from frameworks to analytics platforms.
Hosting panels
Web frameworks
Analytics
JavaScript libraries
Tag managers
Operating systems
Programming languages
Security
Video players
Web servers
JavaScript libraries
Web frameworks
Frequently asked questions
4.8
40,000 users



